new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors




Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12016009584004/07/16 Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
22016007441303/17/16 Substituted diketopiperazines and their use as oxytocin antagonists
32016007568503/17/16 Novel crystal form
42016007577403/17/16 Anti-serum albumin binding variants
52016006982603/10/16 Sample plate for an x-ray powder diffraction apparatus
62016003044202/04/16 Novel compounds
72016002419701/28/16 Antibodies against amyloid-beta peptide
82016000971601/14/16 2 - (azaindol-2-yl) benz imidazoles as pad4 inhibitors
92016001011101/14/16 Production methods
102016000222001/07/16 Muscarinic acetylcholine receptor antagonists
112015036829212/24/15 Method of producing a protein
122015036103912/17/15 Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor
132015036117612/17/15 Ligands that bind tgf-beta receptor ii
142015034289712/03/15 Polypeptide loaded poca nanoparticles for oral administration
152015034315912/03/15 Inhaler device
162015032804411/19/15 Guide device for a liquid dispenser
172015032822611/19/15 Novel compounds
182015031384111/05/15 Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
192015030605810/29/15 Composition comprising a single variable domain and camostat mesylate (cm)
202015030748510/29/15 3 -amino- pyrazole derivatives useful against tuberculosis
212015029761410/22/15 Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions
222015029912110/22/15 Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
232015029917710/22/15 Novel polymorphs and salts
242015029922310/22/15 2-substituted cephem compounds
252015028445410/08/15 Anti-serum albumin binding variants
262015026553909/24/15 Formulation for retinoid-containing soft gelatin capsules
272015025114809/10/15 Container system for mixing and dispensing a drink
282015023847008/27/15 Muscarinic acetylcholine receptor antagonists
292015023242308/20/15 Chemical process
302015020917807/30/15 Liquid droplet dispenser
312015020931907/30/15 Compositions comprising an antibody and camostat mesylate (cm)
322015021076707/30/15 Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
332015021201607/30/15 Sample plate for an x-ray powder diffraction apparatus
342015020217207/23/15 Novel use
352015020385107/23/15 Inhibitors of bromodomain-containing protein pcaf for the treatment of autoimmune and inflammatory diseases or for the treatment of cancer
362015019756507/16/15 Novel ligand
372015018242707/02/15 Silica abrasive-free dentifrice composition
382015016650806/18/15 Novel compounds
392015015764006/11/15 Novel compounds
402015010817804/23/15 Re-sealable container
412015010538704/16/15 Substituted diketopiperazines and their use as oxytocin antagonists
422015009975604/09/15 Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
432015009341404/02/15 Modified antigens
442015009344004/02/15 Aggregate nanoparticulate medicament formulations, manufacture and use thereof
452015008034303/19/15 Benzofuran compounds for the treatment of hepatitis c virus infections
462015008036903/19/15 Novel compounds
472015006420103/05/15 Antigen binding proteins to oncostatin m (osm)
482015006550703/05/15 Novel compounds
492015004537502/12/15 Novel compounds
502015000410501/01/15 Novel composition
512014037848712/25/14 Tricyclic compounds, preparation methods, and their uses
522014037126412/18/14 Muscarinic acetylcholine receptor antagonists
532014033508311/13/14 Methods of treatment and prevention of eye diseases
542014031197710/23/14 Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
552014028813309/25/14 3 -amino- pyrazole derivatives useful against tuberculosis
562014022725908/14/14 Modified proteins and peptides
572014022726408/14/14 Drug fusions and conjugates with extended half life
582014020560407/24/14 Antigen binding constructs
592014020566107/24/14 Formulation for retinoid-containing soft gelatin capsules
602014020021807/17/14 Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
612014019340707/10/14 Drug fusions and conjugates
622014018775007/03/14 Methods for selecting protease resistant polypeptides
632014017971506/26/14 2,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
642014015870406/12/14 Medicament dispenser
652014014099605/22/14 Anti-serum albumin biding variable domains
662014011643405/01/14 Dry powder inhaler compositions
672014011292904/24/14 Tumour necrosis factor receptor 1 antagonists
682014011388804/24/14 Novel combination of therapeutic agents
692014011392204/24/14 Compounds
702014010589404/17/14 Humanized anti-il-18 antibodies
712014010591504/17/14 Bcma (cd269/tnfrsf17) - binding proteins
722014007631403/20/14 Manifold for use in medicament dispenser
732014008086303/20/14 Muscarinic acetylcholine receptor antagonists
742014005690002/27/14 Method for inhibiting binding to b-cell receptor
752014005810502/27/14 Substituted diketopiperazines and their use as oxytocin antagonists
762014005071902/20/14 Antibodies
772014005172002/20/14 N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
782014003898902/06/14 Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
792014002359601/23/14 Novel composition
802014002455801/23/14 Method of treatment
812014000517701/02/14 Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
822014000518801/02/14 Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
832013034546512/26/13 Process for the preparation of retigabine
842013033698912/19/13 Methods of identifying a patient population
852013031590111/28/13 Novel uses
862013031704111/28/13 Compounds
872013031028111/21/13 Novel antigen binding proteins
882013030233511/14/13 Ligands that bind tgf-beta receptor ii
892013026771710/10/13 Process for the preparation of atovaquone
902013026118510/03/13 Benzamide derivatives as ep4 receptor agonists
912013025172409/26/13 Antigen binding proteins to oncostatin m (osm)
922013025318809/26/13 Novel compounds
932013023750109/12/13 Benzofuran compounds for the treatment of hepatitis c virus infections
942013022420408/29/13 Method of treatment based on atad2 inhibitors
952013021315408/22/13 Method of determining cleanliness
962013021339408/22/13 Dispensing device
972013021765808/22/13 Pyrazole compounds acting against allergic, inflammatory and immune disorders
982013021089208/15/13 Method of treatment
992013020370508/08/13 Pyrazole compounds acting against allergic, immune and inflammatory conditions
1002013020380208/08/13 3 -amino- pyrazole derivatives useful against tuberculosis
1012013019641208/01/13 Magi polynucleotides, polypetides, and antibodies
1022013018925507/25/13 Fusions and conjugates of insulinotropic agents
1032013013133805/23/13 Substituted diketopiperazines as oxytocin antagonists
1042013011813205/16/13 Machine and pharmaceutical and pharmaceutical-like product assembly
1052013010969005/02/13 Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
1062013010278304/25/13 Substituted diketopiperazines and their use as oxytocin antagonists
1072013007819803/28/13 Novel use
1082013005337502/28/13 Amino-quinolines as kinase inhibitors
1092013003947002/14/13 Sample plate for an x-ray powder diffraction apparatus
1102013004098402/14/13 7-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
1112013003001201/31/13 Compounds
1122013003001501/31/13 Muscarinic acetylcholine receptor antagonists
1132013002354101/24/13 Voltage-gated sodium channel blockers
1142013001249101/10/13 Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
1152012031620212/13/12 Compounds which have activity at m1 receptor and their uses in medicine
1162012030972512/06/12 Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
1172012030978912/06/12 Compounds which have activity at m1 receptor and their uses in medicine
1182012028854411/15/12 Novel retigabine composition
1192012027727911/01/12 Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
1202012025146810/04/12 Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
1212012024074209/27/12 Novel device
1222012024517109/27/12 Benzpyrazole derivatives as inhibitors of pi3 kinases
1232012023855909/20/12 Novel compounds
1242012023857109/20/12 Indazole derivatives as pi 3-kinase
1252012023206109/13/12 Novel compounds
1262012020774908/16/12 Dosing regimen
1272012020281108/09/12 Novel compounds
1282012015744606/21/12 Medical use
1292012015749106/21/12 Muscarinic acetylcholine receptor antagonists
1302012015749206/21/12 Antibiotic drug
1312012014971106/14/12 Piperidine derivatives used as orexin antagonists
1322012014973106/14/12 New medical use
1332012012868905/24/12 Anti-il-23 immunoglobulins
1342012012977805/24/12 Ligand that bind tgf-beta receptor rii
1352012011464705/10/12 Anti-serum album single variable domains
1362012010013704/26/12 Immunoglobulins
1372012010108304/26/12 S1p1 agonists comprising a bicyclic n-containing ring
1382012010108604/26/12 Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
1392012010112404/26/12 1,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
1402012010113404/26/12 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
1412012010113604/26/12 5-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
1422012006517703/15/12 Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
1432012005896303/08/12 Macrolides with anti-inflammatory activity
1442012004625802/23/12 Novel crystalline pharmaceutical product
1452012004646902/23/12 Process for the preparation of a biphenyl-2-yl carbamic acid ester
1462012003982002/16/12 Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
1472012004099102/16/12 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
1482012004102702/16/12 Benzimidazoles which have activity at m1 receptor and their uses in medicine
1492012004102802/16/12 Benzimidazoles which have activity at m1 receptor and their uses in medicine
1502012003431202/09/12 4-isopropyl-3-methylphenol for the treatment of inflammation
1512012000632201/12/12 Drug dispenser
1522012000422901/05/12 Substituted diketopiperazines and their use as oxytocin antagonists
1532011031937112/29/11 Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1542011030569212/15/11 Antigen-binding contructs
1552011030569312/15/11 Anitigen-binding constructs
1562011028809811/24/11 Novel compounds
1572011028190911/17/11 Substituted quinoline derivatives as h1 receptor antagonists
1582011027565511/10/11 Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1592011027566111/10/11 Tricyclic nitrogen compounds used as antibacterials
1602011026973811/03/11 Compounds
1612011026997011/03/11 Phenethanolamine derivatives for treatment of respiratory diseases
1622011026358810/27/11 Tricyclic compounds as glutamate receptor modulators
1632011025375210/20/11 Nozzle for a nasal inhaler
1642011025607410/20/11 Novel use
1652011024547010/06/11 Immunoglobulins
1662011023779209/29/11 Quinoline derivatives and their use as 5-ht6 ligands
1672011019027408/04/11 Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1682011017806307/21/11 Benzpyrazol derivatives as inhibitors of pi3 kinases
1692011016615007/07/11 Anhydrous crystal form of ovrepitant maleate
1702011015087106/23/11 Treatment of an autoimmune disease using il-18 antagonists
1712011015226206/23/11 Novel compounds
1722011014282406/16/11 Antibodies against amyloid-beta peptide
1732011014415106/16/11 Novel process, salts, composition and use
1742011013569506/09/11 Oral dosage form for controlled drug release
1752011013042306/02/11 Compounds which have activity at m1 receptor and their uses in medicine
1762011011719005/19/11 Pharmaceutical formulations
1772011011826105/19/11 Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1782011006164603/17/11 Drug dispenser
1792011006474003/17/11 Antigen binding proteins
1802011006572503/17/11 Triazole amide derivatives for use in therapy
1812011005916703/10/11 Encapsulation of biologically active agents
1822011005997903/10/11 Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1832011004502702/24/11 Adjuvant
1842011004613702/24/11 Pyrazole derivatives as p2x7 modulators
1852011003452402/10/11 Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1862011002157801/27/11 Compounds which potentiate the ampa receptor and uses thereof in medicine
1872011000939401/13/11 Tricyclic nitrogen compounds and their use as antibacterial agents
1882011000963101/13/11 Phenethanolamine derivatives for treatment of respiratory diseases
1892010032999612/30/10 Novel combination of therapeutic agents
1902010032402212/23/10 Novel compounds
1912010031657912/16/10 Novel use of alkyl phosphate esters
1922010031766612/16/10 Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1932010031767212/16/10 Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1942010030808212/09/10 Dispensing device
1952010031170612/09/10 Method of treatment of allergic rhinitis
1962010031173412/09/10 Spiro compounds useful as antagonists of the h1 receptor
1972010030382112/02/10 Immunoglobulins
1982010030510712/02/10 Quinoline derivatives and their use as 5-ht6 ligands
1992010030512712/02/10 Novel compounds
2002010030516612/02/10 Novel compounds
2012010029222411/18/10 Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
2022010029229511/18/10 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
2032010028615211/11/10 N-phenyl hydrazides as modulators of the ghrelin receptor
2042010027590911/04/10 Actuator for an inhaler
2052010027385310/28/10 Novel isoindol derivatives as ep4 receptor agonists
2062010026769110/21/10 Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
2072010026773410/21/10 N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
2082010025619910/07/10 Crystalline form of an antimalarial compound
2092010025691910/07/10 Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
2102010023966609/23/10 Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
2112010022418509/09/10 Actuator for an inhaler
2122010022234909/02/10 Quinoline derivatives used to treat inflammatory and allergic diseases
2132010021679908/26/10 Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
2142010021683708/26/10 Glycine transport inhibitors
2152010021067208/19/10 Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
2162010020325608/12/10 Method and the application of powder material to substrates
2172010020424208/12/10 Piperazine derivative having affinity for the histamine h3 receptor
2182010020427308/12/10 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2192010019767908/05/10 Compounds
2202010019769908/05/10 I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
2212010019076407/29/10 Novel compounds
2222010018477007/22/10 Compounds
2232010018499607/22/10 Process of amide formation
2242010017569807/15/10 Capsule
2252010017406507/08/10 Compounds
2262010014809106/17/10 Method and system for rapid phase luminescense spectroscopy analysis
2272010015219506/17/10 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
2282010014401606/10/10 Apparatus for the disruption of animal cells
2292010014475506/10/10 Novel compounds
2302010014482906/10/10 Novel receptor antagonists and their methods of use
2312010014504006/10/10 Benzazepine derivatives for the treatment of neurological disorders
2322010013727606/03/10 Compounds which potentiate ampa receptor and uses thereof in medicine
2332010013735306/03/10 Tricyclic compounds as antibacterials
2342010013737806/03/10 Pyridine compounds for the treatment of prostaglandin mediated diseases
2352010013742806/03/10 Oxygen containing heterocycles as glycine transporter inhibiting compounds
2362010013058305/27/10 Prolinamide derivatives as modulators of voltage-gated sodium channels
2372010011352105/06/10 Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
2382010011352805/06/10 Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
2392010011379605/06/10 Indole derivatives as s1p1 receptor
2402010010565204/29/10 Purines as cysteine protease inhibitors
2412010010568804/29/10 Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
2422010010575404/29/10 5-(4phenyl)prolinamide for treatment of epilepsy
2432010008742404/08/10 Tricyclic nitrogen containing heterocycles as antibacterial agents
2442010008750204/08/10 Indazoles used to treat estrogen receptor beta mediated disorders
2452010008766704/08/10 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
2462010008183004/01/10 Methods of synthesizing n-hydroxysuccinimidyl carbonates
2472010007595303/25/10 Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
2482010007598203/25/10 Pyridinone derivative for the treatment of premature ejaculation
2492010006816603/18/10 Oral composition comprising dimethicone copolyol



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###